Advertisement

Organisation › Details
Jeito Capital (Group)
Founded in 2018 and launched in January 2020 by Rafaèle Tordjman, JEITO CAPITAL, a portfolio management company approved by the Autorité des marchés financiers under number GP-19000043, is an independent investment company specialising in private equity. JEITO CAPITAL's mission is to identify and support the next generation of pioneering entrepreneurs in the field of medical innovation, through the implementation of a continuous model of significant financing aimed at accelerating time to market. Through its first fund, JEITO I, JEITO CAPITAL offers its investors the opportunity to support the growth of some fifteen start-ups with the potential to become future unicorns. The new investment company brings together a team of international experts in the drug value chain, combining scientific expertise, clinical development, patent protection and marketing. *
![]() |
Start | 2018-06-25 established |
![]() |
Industry | venture capital |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017) |
Person 2 | Clancy, Annette (Enyo Pharma 201806 Chair of Board of Directors) | |
![]() |
Region | Paris |
Country | France | |
Street | 33 rue La Fayette | |
City | 75009 Paris | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Jeito Capital. (1/15/20). "Press Release: Rafaèle Tordjman Launches Jeito Capital, a New Private Equity Company Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of Jeito I at €200 Million". Paris. | ||
Record changed: 2020-12-16 |
Advertisement

More documents for Jeito Capital (Group)
- [1] InnoSkel S.A.S.. (12/14/20). "Press Release: InnoSkel Launches with €20 Million Series A Financing". Copenhagen....
- [2] Jeito Capital. (11/13/20). "Press Release: Sanofi Selects Jeito Capital as Its First Investment into a Private French-based Fund". Paris....
- [3] Jeito Capital. (1/15/20). "Press Release: Rafaèle Tordjman Launches Jeito Capital, a New Private Equity Company Dedicated to Biotech-biopharmaceuticals, and Announces the Closing of Jeito I at €200 Million". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top